Wegener Polyangiitis - Pipeline Review, H2 2015 Is Released Wegener Polyangiitis - Pipeline Review, H2 2015 Summary Global Markets Direct s, Wegener Polyangiitis - Pipeline Review, H2 2015, provides an overview of the Wegener Polyangiitis s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Wegener Polyangiitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wegener Polyangiitis and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope The report provides a snapshot of the global therapeutic landscape of Wegener Polyangiitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Wegener Polyangiitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Wegener Polyangiitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Wegener Polyangiitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Wegener Polyangiitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Wegener Polyangiitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing 1
strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Browse Complete Report with TOC http://www.idatainsights.com/reports-landingpage.php?id=179122/wegener-polyangiitis-pipeline-review-h2-2015 To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landingpage.php?id=179122/wegener-polyangiitis-pipeline-review-h2-2015\ Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Wegener Polyangiitis Overview 7 Therapeutics Development 8 Pipeline Products for Wegener Polyangiitis - Overview 8 Wegener Polyangiitis - Therapeutics under Development by Companies 9 Wegener Polyangiitis - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Unknown Stage Products 13 Wegener Polyangiitis - Products under Development by Companies 14 Wegener Polyangiitis - Companies Involved in Therapeutics Development 15 Bionovis SA 15 Bristol-Myers Squibb Company 16
2
ChemoCentryx, Inc. 17 Coherus BioSciences, Inc. 18 Epirus Biopharmaceuticals, Inc. 19 Genor BioPharma Co., Ltd. 20 GlaxoSmithKline Plc 21 Hospira, Inc. 22 Panacea Biotec Limited 23 Sandoz International GmbH 24 The International Biotechnology Center (IBC) Generium 25 Wegener Polyangiitis - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 abatacept - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 belimumab - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 3
CCX-168 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 rituximab biosimilar - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 rituximab biosimilar - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 rituximab biosimilar - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 rituximab biosimilar - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 rituximab biosimilar - Drug Profile 48 Product Description 48 Mechanism of Action 48 4
R&D Progress 48 rituximab biosimilar - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 rituximab biosimilar - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 rituximab biosimilar - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 rituximab biosimilar - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Wegener Polyangiitis - Recent Pipeline Updates 53 Wegener Polyangiitis - Dormant Projects 62 Wegener Polyangiitis - Discontinued Products 63 Wegener Polyangiitis - Product Development Milestones 64 Featured News & Press Releases 64 Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis 64 5
Appendix 65 Methodology 65 Coverage 65 Secondary Research 65 Primary Research 65 Expert Panel Validation 65 Contact Us 65 Disclaimer 66" width="80" height="40" />Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Wegener Polyangiitis Overview 7 Therapeutics Development 8 Pipeline Products for Wegener Polyangiitis - Overview 8 Wegener Polyangiitis - Therapeutics under Development by Companies 9 Wegener Polyangiitis - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Unknown Stage Products 13 Wegener Polyangiitis - Products under Development by Companies 14 6
Wegener Polyangiitis - Companies Involved in Therapeutics Development 15 Bionovis SA 15 Bristol-Myers Squibb Company 16 ChemoCentryx, Inc. 17 Coherus BioSciences, Inc. 18 Epirus Biopharmaceuticals, Inc. 19 Genor BioPharma Co., Ltd. 20 GlaxoSmithKline Plc 21 Hospira, Inc. 22 Panacea Biotec Limited 23 Sandoz International GmbH 24 The International Biotechnology Center (IBC) Generium 25 Wegener Polyangiitis - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 abatacept - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 belimumab - Drug Profile 38 7
Product Description 38 Mechanism of Action 38 R&D Progress 38 CCX-168 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 rituximab biosimilar - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 rituximab biosimilar - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 rituximab biosimilar - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 rituximab biosimilar - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 8
rituximab biosimilar - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 rituximab biosimilar - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 rituximab biosimilar - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 rituximab biosimilar - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 rituximab biosimilar - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Wegener Polyangiitis - Recent Pipeline Updates 53 Wegener Polyangiitis - Dormant Projects 62 Wegener Polyangiitis - Discontinued Products 63 Wegener Polyangiitis - Product Development Milestones 64 9
Featured News & Press Releases 64 Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis 64 Appendix 65 Methodology 65 Coverage 65 Read More http://www.idatainsights.com/reports-landing-page.php?id=179122/wegener-polyangiitispipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.
10